TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,695,062 | -61.1% | 972,602 | -33.1% | 1.42% | -53.7% |
| Q2 2023 | $22,344,653 | -36.5% | 1,454,730 | -7.0% | 3.07% | -32.3% |
| Q1 2023 | $35,165,252 | +299.9% | 1,563,595 | +274.0% | 4.54% | +236.5% |
| Q4 2022 | $8,792,622 | -14.4% | 418,099 | +0.3% | 1.35% | -37.7% |
| Q3 2022 | $10,268,000 | -65.7% | 416,729 | -66.3% | 2.16% | -71.7% |
| Q2 2022 | $29,928,000 | +33.3% | 1,235,151 | +41.8% | 7.64% | +5.0% |
| Q1 2022 | $22,444,000 | +297.1% | 870,918 | +378.3% | 7.28% | +141.0% |
| Q4 2021 | $5,652,000 | – | 182,103 | – | 3.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |